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ficients were used to assess the level of association. RE-
SULTS: 81 patients participated in the study. Mean age
of the sample was 57.3 (SD  10.1) years, 89% (n  72)
were female. The average disease duration among pa-
tients was 14.5 (SD  10.6) years. RAQoL scores were
relatively strongly correlated (Pearson coefficient  0.662)
with HAQ scores. The EQ-5D index scores showed higher
correlation (0.627) with HAQ than the Visual Analogue
Scale of EQ-5D (0.463). The Pearson Correlation Coeffi-
cient between RAQoL and EQ-5D index scores was
0.515, and between RAQoL and EQ-5D VAS scores was
0.396. CONCLUSIONS: Results suggest that the Hun-
garian RAQoL is a valid instrument of measuring QoL of
rheumatoid arthritis patients. The EQ-5D index provides
also appropriate results, and can be proposed for cost-
utility analyses. However EQ-5D VAS scores are not rec-
ommended to describe the QoL of patients with rheuma-
toid arthritis.
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OBJECTIVES: The purpose of this study is to examine
the cost-effectiveness (CE) of rofecoxib versus NSAIDs in
the treatment of osteoarthritis. METHODS: The authors
used decision-analysis from a societal perspective to
model a hypothetical cohort of osteoarthritis patients on
long-term NSAID therapy. Incremental cost per QALY
(C/QALY) estimates were calculated for a hypothetical
trial population and for patients at high risk of G.I. ad-
verse events. High-risk patients were defined in the litera-
ture as having four risk factors combined: history of G.I.
bleeds, history of peptic ulcer, cardiovascular disease and
age 75 years or greater. All costs were expressed in 1997
prices. Utility estimates were obtained from a separate
analysis of pharmacy claims data including the Health
Utilities Index Mark 2 from a large HMO. Confidence
intervals were assessed using the maximum and mini-
mum values from the literature. Univariate sensitivity and
threshold analysis were conducted. RESULTS: The C/
QALY range is $5,658 to $108,831 for osteoarthritis pa-
tients; base case C/QALY is $103,597 for all osteoarthri-
tis patients, $9,374 for high-risk patients. Rofecoxib is
cost-effective (C/QALY $50,000) if the incidence of
perforations, ulcers and bleeds (PUB) is 0.098 per year or
greater. Sensitivity: the most sensitive parameters were:
symptomatic dyspepsia utility; rofecoxib price; symptom-
atic peptic ulcer utility; incidence of G.I. symptoms;
NSAID price and incidence of PUBs. However, the pa-
rameters with greatest uncertainty and variability in the
literature are incidence of PUBs and G.I. symptoms.
CONCLUSION: The point estimate C/QALY of rofe-
coxib for all osteoarthritis patients varies from very cost-
effective to not cost-effective depending on assumptions
for the probability of PUBs and G.I. symptoms. Rofe-
coxib is cost saving for patients at high risk of developing
G.I. complications.
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OBJECTIVE: To evaluate the correlation between gen-
eral measures of function and well-being, as measured by
the 8 domains of the SF-36, with arthritis specific mea-
sures of function and symptom frequency. METHODS:
We identified 606 patients from a longitudinal, observa-
tional study of RA (RAPOLO). Patients completed tele-
phone interviews about arthritis specific function (HAQ,
RA Status and Symptoms), the SF-36 domains, Physical
and Mental Summary Scores (PCS, MCS) and the Arthri-
tis Specific Health Index (ASHI). We present correlations
between the SF-36 domains, PCS, MCS and ASHI with
selected arthritis measures. All correlations are presented
as absolute values. RESULTS: All correlations were in
the anticipated direction. A correlation 0.6  good–ex-
cellent, and 0.4  below average. The HAQ was highly
correlated with the SF-36 physical scales, and had weak
correlations with the emotional function scales and the
ASHI. Other arthritis specific scales (joint swelling, joint
pain, morning stiffness, RA fatigue and RA pain) were
strongly correlated with the ASHI, the SF-36 pain, physi-
cal function, role function-physical and energy/fatigue
scales; and had weak correlations with the emotional
functioning and general health scales. CONCLUSIONS:
In RA patients, the SF-36 measures aspects of functioning
and well-being not covered by the arthritis specific mea-
sures, especially in the areas of emotional functioning.
This is indicated by the moderate to weak correlations
between the arthritis specific measures and the domains
of emotional function, role emotional function, and men-
tal health and the MCS.
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OBJECTIVE: To compare osteoporosis treatment charges
among patients treated with an estrogen versus a selective
estrogen receptor modulator (SERM) in a managed care
population. METHODS: Patients 40 years of age with a
